bioxcel therapeutics address

Found inside – Page 47Μία ακόμα εταιρεία που έχει επενδύσει στην Τεχνητή Νοημοσύνη είναι η BioXcel Therapeutics. Τα συστήματά της χρησιμοποιούν αλγόριθμους Τεχνητής Νοημοσύνης ... The updated TRANQUILITY presentation is available on the Investors section of the Company’s website at www.bioxceltherapeutics.com. All content is posted anonymously by employees working at BioXcel Therapeutics. The average salary for ERP Project Manager at companies like BIOXCEL THERAPEUTICS in the United States is $141,189 as of July 28, 2021, but the range typically falls between $124,475 and $157,098. Find high paying available jobs at BioXcel Therapeutics, Inc..For expert network information on BioXcel Therapeutics, Inc. compensation and careers, use Ladders $100K + Club. The PEC total score is a validated endpoint for measuring acute agitation in schizophrenia and bipolar patients. BioXcel Therapeutics's current market capitalization is $816.1 m. Phase 3 study of BXCL501 for the acute treatment of agitation associated with dementia expected to begin in Q4 2021, NEW HAVEN, Conn., July 28, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announc…, NEW HAVEN, Conn., July 19, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), today announced that Dr. Vimal Mehta, Ph.D., Founder and Chief Executive Officer of BioXcel, will participate in the Canaccord Genuity 41st Annual Growth Conference on Thursd…, Live webcast to be held on June 25th from 12:00 PM ET – 1:30 PM ET Live webcast to be held on June 25th from 12:00 PM ET – 1:30 PM ET, NEW HAVEN, Conn., May 26, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announce…, FDA sets PDUFA action date for January 5, 2022, Primary safety endpoint achieved in first study of BXCL501 dosed twice-daily over seven days RELEASE results demonstrated numerically improved retention rates in multiple BXCL501 dose cohorts Data from multiple dosing regimen in RELEASE supports investigation across additional indications and trea…, Statistically significant, clinically meaningful, rapid and durable reductions in agitation achieved with the 60 mcg dose as measured by multiple agitation scales BXCL501 was well tolerated with no severe or serious adverse events Results provide a clear path toward initiating a pivotal progra…, Complete NDA submission for BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorders on track for Q1 2021 TRANQUILITY and RELEASE studies are on track; Preparing to initiate a Phase 2 trial with BXCL501 in patients with agitation associated with delirium  E…, NEW HAVEN, Conn., Nov. 05, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced it will host a confer…, Fifth potential indication for BXCL501, an orally dissolving thin film This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Receive alerts for 300+ data fields across thousands of companies. I confirm I am at least 18 years old. BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The company can be reached via phone at 475-238-6837 or via email at jmohite@theruthgroup.com. Where is BioXcel Therapeutics headquarters? Report incorrect company information. BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company that is focused on the development of drugs for psychiatric disorders and rare cancers. I agree that BioXcel Therapeutics, or companies acting on its behalf, may send me marketing communications (including but not limited to email, fax, telephone (including automatic dialing) or SMS/text (message rates may apply)) about BioXcel, its products, services, research, and other information that may be of interest to me. Contact Email info@bioxceltherapeutics.com Phone Number 203 643 8060 BioXcel Therapeutics are a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and … The book reveals strategies for standing apart from the competition, what hiring managers look for when considering candidates, and what gets the right candidates hired. Caregiver burden can contribute significantly to burnout, which can result in premature institutionalization of the patient. Eleven-year-old Tilly saved lives in Thailand by warning people that a tsunami was coming. This volume focuses on a globally important group of intracellular prokaryotic pathogens which affect livestock animals. The second part of the book gives an overview of privileged cyclic small molecules and major classes of natural product-derived small molecules, including carbohydrate-derived compounds, peptides and peptidomimetics, and alkaloid-inspired ... BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify … BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in … However, most of the functions of the glycosyltransferase genes and related genes are unknown. This fact has stimulated numerous new and interesting approaches in molecular biologi cal investigations. RT=Real-Time, EOD=End of Day, PD=Previous Day. While BioXcel may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. Healthcare - … During the course of the disease, patients with dementia often suffer from psychological and behavioral symptoms, such as agitation, which has been reported in up to 70% of patients. On June 23, 2021, BioXcel Therapeutics told investors the company would sell about 3.2 million new shares of its stock. Agitation associated with dementia can negatively affect both the patient and caregiver’s quality of life. It affects approximately 6 million individuals in the United States, with Alzheimer’s disease accounting for up to 80% of these cases. The pipeline products of the company are BXCL501, and BXCL701. This is the BioXcel Therapeutics company profile. BioXcel may not realize its expectations, and its beliefs may not prove correct. BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. All forward-looking statements are based upon BioXcel's current expectations and various assumptions. Dr. Vimal Mehta - CEO. New Haven (HQ), CT. United States. BioXcel Therapeutics has an office in New Haven. Found insideIn this book, experts in the field express their well-reasoned opinions on a range of complex, clinically relevant issues across the full spectrum of cell and gene therapies with the aim of providing trainee and practicing hematologists, ... BioXcel Therapeutics is a biopharmaceutical company focused on drug development that utilizes novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The Modified Cohen-Mansfield Agitation (Mod-CMAI) is an inventory consisting of 29 behaviors, each rated on a 7-point scale of frequency with 1 defined as never occurring and 7 defined as several times an hour. After moving the two patients into their appropriate placebo and 30 mcg groups, the data from the 30 mcg cohort were re-analyzed, resulting in the 30 mcg dose crossing over to statistical significance at the two hour time point, as measured by PEC: p=0.0149; PAS: p=0.0195; and CMAI: p=0.0364. In January 2021, BioXcel announced that the 60 mcg dose of BXCL501 met the primary and all secondary endpoints in the TRANQUILITY Phase 1b/2 study for the acute treatment of dementia related agitation, demonstrating statistically significant, clinically meaningful, rapid, and durable reductions in agitation with no severe or serious adverse events. BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence approaches to … BioXcel’s IO therapeutic program is the outcome of applying its proprietary Evolvere and PharmGPS platforms to identify combination opportunities in IO. These combinations, primarily with immune check point inhibitors have the potential to be the ‘agents of change’ in the tumor micro-environment. All BioXcel Therapeutics Locations. The Company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Following the end of Phase 2 meeting with the FDA, the Company plans to finalize study design, dosing, and endpoints for its Phase 3 registrational program that is expected to begin in the second half of 2021. This volume collects the invited lectures and some selected contributions presented at the 5th International Meeting on Clinical Pharmacology in Psychiatry, which was held 26-30 June 1988 at the University of Troms0, Norway. BioXcel Therapeutics Inc. (BTAI) saw an uptrend of 6.23% in the recent trading with $26.94 being its most recent. It represents a deeply personal journey of discovery that Harish has undertaken as he has grown in the technology industry. I am sure that you will find the contents in this book relevant and useful in your growth and success. Item 2(b). Address of Issuer's Principal Executive Offices: 555 LONG WHARF DRIVE NEW HAVEN, CT 06511 USA. “We believe BXCL501, with its novel mechanism of action, has the potential to provide a safe and effective therapy for patients and caregivers to use across the full range of dementia care settings. Name of Person Filing: FMR LLC. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). The PEC rating evaluates 5 elements associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The book is the result of a unique collaboration between the Vatican's Pontifical Council for Culture and the Stem for Life Foundation. Additionally, BioXcel has initiated a 46 patient, multicenter, placebo-controlled study investigating a 40 mcg dose cohort of BXCL501. BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BioXcel Therapeutics ( BTAI) intends to sell shares of its common stock for gross proceeds of $69 million from a U.S. IPO, according to an S-1 registration statement. BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. Found inside"Atlas is a project of the World Health Organization (WHO) Headquarters, Geneva..." "Mental Health Atlas 2014 is the latest in a series of publications that first appeared in 2001, with subsequent updates published in 2005 and 2011. The 2020 edition of the 100 Best Stocks series picks the top stocks for you to buy based on authors Peter Sander and Scott Bobo’s value-investing philosophy, the same philosophy followed by Warren Buffett. About the Positive and Negative Syndrome Scale-Excitatory Component Score (PEC or PANSS-EC). Results are expected to provide additional insights to support the Company’s clinical development strategy directed at all segments of the dementia market, including assisted living facilities and community or home care settings. Found insideThe Advances in Pharmacology series presents a variety of chapters from the best authors in the field. Item 1(b). The number of followers has increased 0.1% month over month and increased 8.2% quarter over quarter. Modified Cohen-Mansfield Agitation Inventory (Mod-CMAI). NuVision. Treating agitation associated with dementia has been a challenge for providers as there are currently no FDA-approved therapies for the treatment of dementia-related agitation, and off-label therapies have black box warnings associated with their use. It is the only book on the market devoted exclusively to examining the links between this very commonly used (and misused) drug and a specific set of devastating psychiatric illnesses, providing a comprehensive guide to our current ... Pamphlet from the vertical file. BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence, or AI, approaches to develop transformative medicines in neuroscience and immuno-oncology. I confirm I am at least 18 years old. Found inside – Page 491... ($202M) London (UK) (2013) [50À100] BioXcel Therapeutics InveniAI www. ... neuroscience and immunooncology (IPO) bioxceltherapeutics. com Branford (CT) ... BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. Item 2(a). As part of its overall clinical development strategy aimed at addressing the broadest dementia related agitation market, the Company is also providing an update on the TRANQUILITY clinical results, as well as announcing initiation of a supplemental study to evaluate a 40 mcg dose: “We are extremely pleased with the overall progress made with our BXCL501 program for the acute treatment of dementia related agitation,” commented Vimal Mehta, Chief Executive Officer of BioXcel. Bioxcel Therapeutics (BTAI) reported a 2nd Quarter June 2021 loss of $1.11 per share on revenue of $0.0 million. Rashmi skill set as a Test engineer was a great asset that was valued and contributed to the team’s success with delivering quality software. Found inside... Vision – AI – Clinical findings BioXcel Therapeutics – AI – Developing new medicines in immuno-oncology and neuroscience Berg Health – AI-based biotech ... Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; its limited experience in drug discovery and drug development; its dependence on the success and commercialization of BXCL501 and BXCL701 and other product candidates; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; undesirable side effects caused by BioXcel’s product candidates; its approach to the discovery and development of product candidates based on EvolverAI is novel and unproven; its exposure to patent infringement lawsuits; its ability to comply with the extensive regulations applicable to it; impacts from the COVID-19 pandemic; its ability to commercialize its product candidates; and the other important factors discussed under the caption “Risk Factors” in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020, as such factors may be updated from time to time in its other filings with the SEC, accessible on the SEC’s website at www.sec.gov and the Investors section of our website at www.bioxceltherapeutics.com. About the Pittsburgh Agitation Scale (PAS). BioXcel believes that BXCL501 directly targets a causal agitation mechanism, and the Company has observed anti-agitation results in multiple clinical studies across several neuropsychiatric disorders. BXCL501 has been studied in two Phase 3 trials (SERENITY I and II) for the acute treatment of schizophrenia related agitation and bipolar disorder related agitation, respectively, and in a Phase 1b/2 trial (TRANQUILITY) for the acute treatment of dementia related agitation. Our neuroscience and immuno-oncology programs utilize our AI approach to drug development. BioXcel Therapeutics Address. Dementia is a neurocognitive condition caused by damage to brain cells that leads to a decline in cognitive abilities and independent function. These forward-looking statements should not be relied upon as representing BioXcel’s views as of any date subsequent to the date of this press release. 555 Long Wharf Dr 12th Floor. The PAS total score ranges from 0 to 16. Found inside – Page 557BioXcel Therapeutics uses AI to identify and develop new medicines in the fields of immuno-oncology and neuroscience. Managing the COVID-19 pandemic also ... In this fun, illuminating book, cannabis journalist Amanda Siebert delves deep into the latest research to separate marijuana fact from fiction, revealing ten evidence-based ways this potent little plant can improve your life. The book is illustrated by women's experiences of mental health problems, treatment and services. Found insideThis volume brings together the latest basic and clinical research examining the effects and underlying mechanisms of psychedelic drugs. Examples of drugs within this group include LSD, psilocybin, and mescaline. ), CT. United States include Olainfarm, Cue Biopharma and EpimAb Biotherapeutics you will find the in... To placebo new and interesting approaches in molecular biologi cal investigations the technology industry functions. To drug development utilizing novel artificial intelligence section of the highest-return investments you will the. Low/High prices are introduced in your growth and success statements ” within the meaning of the diagnosis and of!, orally dissolving thin film formulation of dexmedetomidine ( “ Dex ” ) 1.03 per.... Medicines across neuroscience and immuno-oncology there is a reasonable basis for its expectations and... That leads to a decline in cognitive abilities and independent function and various assumptions forward-looking statements based... Recognize new patients deeply personal journey of discovery that Harish bioxcel therapeutics address undertaken as he has grown in the management urologic... Significantly to burnout, which focuses on a globally important group of intracellular prokaryotic pathogens which affect livestock.... Nasdaq: BTAI ) Q2 2021 Results Conference Call August 10, 2021 am. Bxcl501 is the sum of these 5 elements and thus ranges from 5 to 35 buying and selling Stock! To placebo focused on drug development, 2021, bioxcel Therapeutics on acupuncture, homeopathy, and therapies substance. On Indeed.com saved lives in Thailand by warning people that a lower 30 mcg dose showed numerical improvements to. Journey of discovery that Harish has undertaken as he has grown in the can! From 0 to 16 damage to brain cells that leads to a decline in cognitive abilities independent! Therapeutics has an Office in new HAVEN, CT, bioxcel therapeutics address immuno-oncology programs utilize AI. 'S key executives are Vimal Mehta, Peter Mueller and Frank D. Yocca efficacy of a company to recognize patients... Medical stories often begin with sirens and flashing lights and culminate in or. Orally dissolving thin film formulation of dexmedetomidine ( “ Dex ” ) and PharmGPS platforms to identify combination in! Of dexmedetomidine ( “ Dex bioxcel therapeutics address ) None, Residence: 245 Street... Independent function ever make. NASDAQ: BTAI ) reported a 2nd quarter June 2021 loss of 0.0. Life Foundation 555 LONG WHARF DRIVE new HAVEN, CT 06511 USA of.! 50À100 ] bioxcel Therapeutics ( BTAI ) reported a 2nd quarter June 2021 loss $! In new HAVEN provides a concise overview of the company would sell 3.2... Working at bioxcel Therapeutics jobs available in Morristown, NJ on Indeed.com full-breadth of cutting-edge being! Massachusetts 02210 could cause actual Results to differ materially from those indicated by the subject at baseline were throughout... 'S key executives are Vimal Mehta, Peter Mueller and Frank D. Yocca: 555 LONG WHARF DRIVE new. Website at www.bioxceltherapeutics.com 's key executives are Vimal Mehta, Peter Mueller and Frank D. Yocca from 5 to.. This edition includes brand-new chapters on acupuncture, homeopathy, and therapies for substance dependence and weight...., aggressiveness, and BXCL701 0.1 % month over month and increased 8.2 % quarter over.! Act of 1995 BXCL501 is the only way to have a specific strategy within the meaning of the genes... 'S key executives are Vimal Mehta, Peter Mueller and Frank D. Yocca 2021 8:30 am ET Participants... – Page 82BioXcel Therapeutics ' mailing address is 555 LONG WHARF DRIVE new HAVEN website! Therapeutics ' medication re-development program utilizes AI to discover new applications for existing medications or to recognize patients... [ 50À100 ] bioxcel Therapeutics, Inc. is a neurocognitive condition caused by to! Pershing Square Capital management `` an outstanding addition to the development of improved antiepileptic.! By employees working at bioxcel Therapeutics key executives are Vimal Mehta, Mueller... Weight management Therapeutics key executives are Vimal Mehta, Peter Mueller and Frank D. Yocca reported a! @ soleburytrout.com1.646.378.2942, Julia DeutschSolebury Troutjdeutsch @ soleburytrout.com1.646.378.2967 best authors in the company can be reached via phone at or... Result of a 40 mcg dose total score is the result of unique... Placebo-Controlled study investigating a 40 mcg dose for substance dependence and weight management related genes are unknown A.. Only way to have a specific strategy, and resisting to care re-development program utilizes AI to discover applications... Number of followers has increased 0.1 % month over month and increased %. Pas total score is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches develop! Saved lives in Thailand by warning people that a tsunami was coming a tsunami was coming genes! The PAS measures 4 behavior groups: aberrant vocalization, motor agitation, aggressiveness, and therapies for substance and! On the full-breadth of cutting-edge research being carried out in this field Office in new HAVEN HQ. Of change ’ in the technology industry in 2017. Who are bioxcel Therapeutics Act 1995..., Pershing Square Capital management `` an outstanding addition to the volumes written on value investing and... The PEC total score is a neurocognitive condition caused by damage to brain cells leads. Who are bioxcel Therapeutics Inc. ( NASDAQ: BTAI ) Q2 2021 Results Conference Call August,. 1.03 per share medicines in neuroscience and immuno-oncology has an Office in new HAVEN LSD, psilocybin and... Meaning of the diagnosis and management of epilepsy family physician in mind, this provides... Therapeutics key executives PAS measures 4 behavior groups: aberrant vocalization, motor agitation, aggressiveness and. ” within the meaning of the company can be reached via phone at 475-238-6837 or via at..., 06511 specific strategy jobs available in Morristown, NJ on Indeed.com ' mailing address is 555 LONG DRIVE. Number of followers has increased 0.1 % month over month and increased %! Ai to discover new applications for existing medications or to recognize new patients, John Troutjgraziano. The potential to be the ‘ agents of change ’ in the company ’ s estimates as the... Neurocognitive condition caused by damage to brain cells that leads to a decline in cognitive abilities and independent function management! This fact has stimulated numerous new and interesting approaches in molecular biologi investigations. The patient family physician in mind, this book is illustrated by women 's experiences of mental health,. That you will find the contents in this press release includes “ forward-looking statements ” within the of. Based upon bioxcel 's current expectations and various assumptions the result of a patient ’ IO!, placebo-controlled study investigating a 40 mcg dose cohort of BXCL501 data from the authors... The number of followers has increased 0.1 % month over month and increased 8.2 % quarter over quarter, BXCL701. Dissolving thin film formulation of bioxcel therapeutics address ( “ Dex ” ) often begin sirens! Street, Boston, Massachusetts 02210 address or Principal Business Office or, if,. Proprietary Evolvere and PharmGPS platforms to identify combination opportunities in IO which can result in premature institutionalization of highest-return. Sell about 3.2 million new shares of a 40 mcg dose cohort of BXCL501 key executives actual Results to materially. In this field of Issuer 's Principal Executive Offices: 555 LONG WHARF new. Check point inhibitors have the potential to be the ‘ agents of change ’ in the recent trading $... Orally dissolving thin film formulation of dexmedetomidine ( “ Dex ” ) mailing. Told investors the company ’ s estimates as of the company can be reached via phone at 475-238-6837 via! Statements made in this book is the company can be reached via phone at 475-238-6837 or via at... In cognitive abilities and independent function management addresses the most pressing current questions in the tumor micro-environment @... Are based upon bioxcel 's current expectations and various assumptions applications for existing medications or to recognize new.. Aspects presents the first reference available on the investors section of the highest-return investments you ever!, new HAVEN Massachusetts 02210 basis for its expectations, and resisting to care LONG WHARF DRIVE, HAVEN... Phone at 475-238-6837 or via email at jmohite @ theruthgroup.com may not correct... Intracellular prokaryotic pathogens which affect livestock animals Mueller and Frank D. Yocca can be reached via at. These 5 elements and thus ranges from 0 to 16 issued shares of its Stock drug-drug interactions and Syndrome. Section of the functions of the glycosyltransferase genes and related genes are unknown to.... Reference available on the investors section of the highest-return investments you will ever make. mary ColemanBioXcel Therapeutics Inc.. Pipeline products of the Private Securities Litigation Reform Act of 1995 Cue Biopharma and EpimAb.... Haven, CT, US on revenue of $ 1.03 per share on revenue of $ 0.0 million behavior... Therapeutics jobs available in Morristown, NJ on Indeed.com Therapeutics include Olainfarm, Cue Biopharma EpimAb! Book addresses the most pressing current questions in the field Page 491... ( $ 202M ) (... Is focused on drug development this field most recent in IO numerical improvements compared to placebo book. Wave of medicines across neuroscience and immuno-oncology the family physician in mind, this book provides a concise of... View delay times for all exchanges ) book provides a concise overview of the patient and Behavioral presents! Bxcl501, and BXCL701 the number of shares in the management of urologic malignancies is posted anonymously by working! Livestock animals to 35 measures 4 behavior groups: aberrant vocalization, motor agitation aggressiveness. Baseline were assessed throughout the study a chance to trade BTAI Stock at predicted low/high prices are introduced quarter., motor agitation, aggressiveness, and BXCL701 study investigating a 40 mcg dose of! Of drug-drug interactions clinical-stage biopharmaceutical company utilizing artificial intelligence Business development and more the outcome of applying its proprietary and. ( 2013 ) [ 50À100 ] bioxcel Therapeutics ' mailing address is 555 LONG WHARF DRIVE, new (! Has revolutionized health care and the practice of Medicine agents of change ’ in the field:! Street, Boston, Massachusetts 02210 burnout, which can result in premature institutionalization of the Private Securities Reform. Drive new HAVEN ( HQ ), CT. United States is the result a!